Index RUT
P/E -
EPS (ttm) -15.45
Insider Own 10.90%
Shs Outstand 50.92M
Perf Week 2.76%
Market Cap 1.54B
Forward P/E -
EPS next Y -3.56
Insider Trans -0.33%
Shs Float 45.37M
Perf Month 13.55%
Income -185.98M
PEG -
EPS next Q -0.83
Inst Own 92.39%
Short Float 18.65%
Perf Quarter 25.19%
Sales 0.00M
P/S -
EPS this Y 92.59%
Inst Trans -10.48%
Short Ratio 13.90
Perf Half Y -24.31%
Book/sh 4.30
P/B 7.01
EPS next Y 2.13%
ROA -54.73%
Short Interest 8.46M
Perf Year 177.81%
Cash/sh 8.37
P/C 3.61
EPS next 5Y -
ROE -222.71%
52W Range 8.43 - 47.97
Perf YTD 40.20%
Dividend Est. -
P/FCF -
EPS past 5Y 1.60%
ROI -49.68%
52W High -37.11%
Beta 2.93
Dividend TTM -
Quick Ratio 19.70
Sales past 5Y -49.91%
Gross Margin 39.53%
52W Low 257.89%
ATR (14) 1.81
Dividend Ex-Date -
Current Ratio 19.70
EPS Y/Y TTM 79.05%
Oper. Margin 0.00%
RSI (14) 59.30
Volatility 6.43% 6.27%
Employees 30
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.11
Target Price 47.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 98.49%
Payout -
Rel Volume 3.53
Prev Close 30.40
Sales Surprise -100.00%
EPS Surprise 9.45%
Sales Q/Q -100.00%
Earnings Aug 07 AMC
Avg Volume 608.76K
Price 30.17
SMA20 7.48%
SMA50 7.87%
SMA200 3.72%
Trades
Volume 2,151,210
Change -0.76%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-04-24 Initiated
Wedbush
Outperform
$45
Jul-16-24 Initiated
Evercore ISI
Outperform
May-02-24 Initiated
Robert W. Baird
Outperform
$50
Mar-01-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$12 → $35
Dec-20-23 Initiated
BTIG Research
Buy
$32
Dec-11-23 Initiated
Jefferies
Buy
$31
Dec-11-23 Initiated
Guggenheim
Buy
$44
May-04-20 Initiated
Piper Sandler
Overweight
$12
Mar-21-19 Initiated
JP Morgan
Overweight
$14
Sep-04-18 Downgrade
Wells Fargo
Outperform → Market Perform
Apr-24-18 Initiated
Evercore ISI
Outperform
$37
Mar-14-18 Reiterated
Needham
Buy
$8 → $12
Show Previous Ratings
Sep-10-24 04:47PM
Aug-07-24 11:53PM
04:05PM
Jul-18-24 08:00AM
Jun-18-24 07:30AM
05:23PM
Loading…
Jun-03-24 05:23PM
(PR Newswire) +5.26%
-7.31%
May-29-24 08:30AM
May-15-24 07:30AM
May-09-24 10:54PM
04:02PM
May-03-24 05:00PM
Apr-01-24 05:00PM
Mar-18-24 08:00AM
Mar-04-24 08:50AM
Mar-01-24 05:25PM
04:05PM
Loading…
Feb-29-24 04:05PM
Feb-26-24 07:30AM
Feb-08-24 07:30AM
Feb-06-24 09:55AM
Feb-05-24 07:30AM
Feb-02-24 05:30PM
Dec-22-23 05:00PM
(PR Newswire) +5.52%
+6.22%
Dec-08-23 07:19AM
Dec-07-23 06:20PM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 05:00PM
Nov-09-23 06:26PM
(Associated Press Finance)
04:05PM
Nov-03-23 05:00PM
08:00PM
Loading…
Oct-30-23 08:00PM
Oct-02-23 06:02PM
Sep-14-23 05:03PM
Sep-07-23 08:40AM
Sep-05-23 07:00AM
Aug-11-23 07:07AM
(Associated Press Finance)
07:00AM
Jul-27-23 07:00AM
Jun-23-23 04:30PM
(PR Newswire) -12.30%
-5.30%
10:31AM
Jun-22-23 10:59AM
08:17AM
May-13-23 08:03AM
May-11-23 08:15AM
07:10AM
07:01AM
Apr-13-23 09:44AM
Apr-12-23 07:00AM
Mar-17-23 05:30PM
Mar-02-23 10:15AM
07:01AM
Feb-12-23 07:40AM
Jan-06-23 07:01AM
Jan-02-23 07:29AM
Dec-14-22 12:00PM
Dec-02-22 04:05PM
(PR Newswire) +18.17%
-5.90%
Nov-30-22 10:38AM
07:01AM
Nov-15-22 04:25PM
Nov-03-22 08:35AM
07:01AM
Oct-21-22 12:27PM
12:06PM
Oct-19-22 04:05PM
Oct-17-22 11:57AM
Oct-04-22 11:05AM
07:01AM
Aug-29-22 04:05PM
(PR Newswire) +16.74%
-13.51%
Aug-27-22 09:18AM
Aug-25-22 11:52AM
Aug-24-22 12:40PM
08:01AM
Aug-22-22 12:28PM
Aug-20-22 10:49AM
Aug-19-22 06:26AM
Aug-18-22 04:05PM
Aug-04-22 08:35AM
07:01AM
Jul-24-22 10:41AM
Jul-08-22 11:14AM
Jul-07-22 11:22AM
Jul-04-22 11:49AM
Jun-29-22 12:34PM
Jun-28-22 11:52AM
10:23AM
Jun-13-22 12:01PM
Jun-09-22 09:56AM
Jun-03-22 10:49AM
Jun-02-22 03:26PM
03:20PM
12:09PM
11:24AM
08:59AM
Jun-01-22 02:25PM
02:22PM
May-31-22 11:26AM
May-26-22 11:18AM
May-25-22 12:07PM
May-23-22 11:46AM
11:33AM
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burrows Scott L Chief Financial Officer Sep 03 '24 Sale 28.17 18,531 522,074 116,422 Sep 05 04:04 PM Fairmount Funds Management LLC Director Apr 25 '24 Option Exercise 0.00 3,639,680 0 4,018,101 Apr 25 04:55 PM
Index RUT
P/E -
EPS (ttm) -2.18
Insider Own 13.25%
Shs Outstand 116.89M
Perf Week -4.78%
Market Cap 1.19B
Forward P/E -
EPS next Y -1.15
Insider Trans -1.21%
Shs Float 101.40M
Perf Month 21.70%
Income -198.76M
PEG -
EPS next Q -0.41
Inst Own 99.46%
Short Float 24.34%
Perf Quarter 19.55%
Sales 132.06M
P/S 8.98
EPS this Y 59.98%
Inst Trans 9.65%
Short Ratio 10.10
Perf Half Y -0.29%
Book/sh 1.60
P/B 6.34
EPS next Y 24.08%
ROA -51.93%
Short Interest 24.68M
Perf Year 72.62%
Cash/sh 3.11
P/C 3.27
EPS next 5Y 9.80%
ROE -148.92%
52W Range 1.76 - 13.17
Perf YTD 214.24%
Dividend Est. -
P/FCF -
EPS past 5Y -48.07%
ROI -50.55%
52W High -22.93%
Beta 1.18
Dividend TTM -
Quick Ratio 8.19
Sales past 5Y 303.42%
Gross Margin 92.01%
52W Low 476.70%
ATR (14) 0.73
Dividend Ex-Date -
Current Ratio 8.46
EPS Y/Y TTM 60.54%
Oper. Margin -136.13%
RSI (14) 49.71
Volatility 8.03% 7.26%
Employees 296
Debt/Eq 1.11
Sales Y/Y TTM 1032.90%
Profit Margin -150.51%
Recom 1.29
Target Price 18.57
Option/Short Yes / Yes
LT Debt/Eq 1.11
EPS Q/Q 63.33%
Payout -
Rel Volume 1.48
Prev Close 10.14
Sales Surprise 6.08%
EPS Surprise 18.68%
Sales Q/Q 494.57%
Earnings Aug 14 AMC
Avg Volume 2.44M
Price 10.15
SMA20 -2.59%
SMA50 2.32%
SMA200 23.91%
Trades
Volume 3,608,832
Change 0.10%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated
Jefferies
Buy
$15
Jan-03-24 Upgrade
Mizuho
Neutral → Buy
$4 → $8
Oct-26-23 Downgrade
Mizuho
Buy → Neutral
$57 → $4
Oct-13-23 Downgrade
Goldman
Buy → Neutral
$32 → $6
Sep-07-22 Initiated
Needham
Buy
$46
Mar-17-22 Initiated
Goldman
Buy
$45
Jun-30-21 Initiated
Mizuho
Buy
$58
May-27-21 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$52
Nov-09-20 Upgrade
Goldman
Neutral → Buy
$34 → $36
Oct-08-20 Initiated
Truist
Buy
$38
Feb-25-20 Initiated
Guggenheim
Buy
$36
Feb-25-20 Initiated
Goldman
Neutral
$30
Feb-25-20 Initiated
Cowen
Outperform
$55
Feb-25-20 Initiated
Cantor Fitzgerald
Overweight
$50
Show Previous Ratings
Sep-19-24 08:00AM
Sep-06-24 01:29AM
Sep-05-24 04:00PM
08:00AM
12:01AM
05:22PM
Loading…
Sep-02-24 05:22PM
Aug-28-24 08:00AM
Aug-22-24 08:00AM
Aug-15-24 01:15PM
(Thomson Reuters StreetEvents) -11.27%
Aug-14-24 09:00PM
05:10PM
04:00PM
Aug-07-24 10:00AM
Aug-02-24 04:00PM
Aug-01-24 04:00PM
07:35AM
Loading…
Jul-29-24 07:35AM
07:30AM
Jul-23-24 02:57PM
08:00AM
Jul-22-24 08:00AM
Jul-19-24 09:40AM
Jul-17-24 09:54AM
Jul-10-24 01:13PM
(Pharmaceutical Technology)
11:23AM
07:48AM
Jul-09-24 04:53PM
08:00AM
Jul-06-24 08:00AM
Jul-03-24 04:00PM
Jul-02-24 07:45AM
(Investor's Business Daily)
09:40AM
Loading…
Jun-17-24 09:40AM
Jun-14-24 09:55AM
Jun-13-24 06:00AM
Jun-10-24 02:30PM
Jun-05-24 04:00PM
08:00AM
Jun-03-24 08:00AM
May-31-24 09:40AM
May-20-24 09:55AM
May-16-24 11:23AM
May-15-24 12:54PM
(Thomson Reuters StreetEvents) +13.65%
12:03PM
09:12AM
08:53AM
08:46AM
08:19AM
07:29AM
04:24AM
03:13AM
May-14-24 08:57PM
04:53PM
04:00PM
May-13-24 08:00AM
May-03-24 04:00PM
Apr-29-24 04:00PM
Apr-10-24 08:00AM
Apr-05-24 04:00PM
(GlobeNewswire) +5.49%
+10.49%
Apr-01-24 07:00AM
Mar-28-24 08:00AM
Mar-19-24 09:55AM
Mar-18-24 09:55AM
Mar-11-24 08:00AM
Mar-10-24 04:00PM
Mar-09-24 04:00PM
Mar-08-24 07:33PM
(Barrons.com) +7.42%
-9.96%
Mar-05-24 04:00PM
Mar-04-24 04:00PM
08:00AM
Mar-01-24 09:55AM
09:40AM
Feb-29-24 05:00PM
11:33AM
Feb-28-24 11:30PM
04:10PM
04:00PM
12:16AM
(Thomson Reuters StreetEvents)
Feb-27-24 08:11AM
05:50AM
Feb-16-24 08:00AM
Feb-06-24 04:00PM
Feb-01-24 03:04PM
Jan-31-24 08:00AM
Jan-29-24 08:00AM
Jan-22-24 08:00AM
Jan-18-24 12:00PM
Jan-14-24 04:00AM
04:00AM
Dec-23-23 07:32PM
Dec-19-23 11:48AM
Dec-18-23 06:02AM
(Pharmaceutical Business Review)
04:58AM
Dec-15-23 05:19PM
05:14PM
05:11PM
Dec-01-23 10:00PM
(GlobeNewswire) +8.15%
+12.56%
Nov-29-23 08:00AM
Nov-17-23 09:35AM
Nov-16-23 11:04PM
Nov-15-23 01:26PM
Nov-14-23 05:04PM
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Welgus Howard G. Director Sep 03 '24 Sale 10.77 10,000 107,695 191,944 Sep 05 05:56 PM Welgus Howard G. Director Sep 03 '24 Proposed Sale 10.77 10,000 107,695 Sep 03 01:37 PM Burnett Patrick See Remarks Aug 19 '24 Sale 8.29 1,728 14,318 194,859 Aug 21 04:39 PM Burnett Patrick Officer Aug 19 '24 Proposed Sale 8.29 1,728 14,318 Aug 19 05:43 PM Matsuda Masaru See Remarks Aug 02 '24 Sale 9.02 5,220 47,064 183,288 Aug 05 04:37 PM Burnett Patrick See Remarks Aug 02 '24 Sale 9.02 13,206 119,106 196,587 Aug 05 04:37 PM Watanabe Todd Franklin See Remarks Aug 02 '24 Sale 9.02 14,487 130,648 846,263 Aug 05 04:37 PM Welgus Howard G. Director Aug 01 '24 Option Exercise 1.68 6,614 11,115 186,953 Aug 05 04:37 PM Welgus Howard G. Director Aug 01 '24 Sale 9.87 10,000 98,696 176,953 Aug 05 04:37 PM Matsuda Masaru Officer Aug 02 '24 Proposed Sale 9.02 5,220 47,063 Aug 02 04:22 PM Burnett Patrick Officer Aug 01 '24 Proposed Sale 9.14 13,026 119,105 Aug 02 04:20 PM Watanabe Todd Franklin Officer Aug 02 '24 Proposed Sale 9.02 14,487 130,648 Aug 02 04:19 PM Welgus Howard G. Director Aug 01 '24 Proposed Sale 9.87 10,000 98,696 Aug 01 04:45 PM Welgus Howard G. Director Jul 01 '24 Option Exercise 1.68 10,000 16,806 190,339 Jul 02 07:13 PM Welgus Howard G. Director Jul 01 '24 Sale 9.31 10,000 93,141 180,339 Jul 02 07:13 PM Welgus Howard G. Director Jun 04 '24 Option Exercise 1.68 10,000 16,806 180,200 Jun 06 04:15 PM Welgus Howard G. Director Jun 04 '24 Sale 8.01 10,000 80,092 170,200 Jun 06 04:15 PM Burnett Patrick See Remarks May 30 '24 Option Exercise 0.00 23,000 0 232,793 May 31 04:50 PM Burnett Patrick See Remarks May 29 '24 Sale 8.72 49,952 435,387 209,793 May 31 04:50 PM Burnett Patrick See Remarks May 30 '24 Sale 8.75 23,000 201,319 209,793 May 31 04:50 PM Matsuda Masaru See Remark May 28 '24 Sale 9.01 1,775 15,988 188,508 May 29 07:38 PM Edwards Larry Todd SVP Chief Commercial Officer May 17 '24 Sale 8.98 7,640 68,582 140,360 May 20 05:12 PM Moore Matthew Richard SVP and Chief Business Officer May 02 '24 Sale 8.74 4,681 40,902 145,505 May 03 04:29 PM Watanabe Todd Franklin See Remarks May 02 '24 Sale 8.74 13,783 120,433 860,750 May 03 04:22 PM Matsuda Masaru See Remark May 02 '24 Sale 8.74 5,016 43,829 185,408 May 03 04:22 PM Burnett Patrick See Remarks May 02 '24 Sale 8.74 9,555 83,490 259,745 May 03 04:22 PM Matsuda Masaru See Remark Mar 04 '24 Sale 11.12 3,760 41,816 190,424 Mar 06 05:14 PM Burnett Patrick See Remarks Mar 04 '24 Sale 11.12 4,782 53,182 269,300 Mar 06 05:12 PM Watanabe Todd Franklin See Remarks Mar 04 '24 Sale 11.12 14,903 165,739 874,533 Mar 06 05:09 PM Moore Matthew Richard SVP and Chief Business Officer Mar 04 '24 Sale 11.12 3,468 38,568 146,020 Mar 06 05:08 PM Heron Patrick J Director Mar 04 '24 Buy 9.50 21,052 199,994 8,785,284 Mar 06 04:28 PM Watanabe Todd Franklin See Remarks Feb 28 '24 Sale 10.60 2,465 26,129 889,436 Mar 01 04:11 PM Burnett Patrick See Remarks Jan 02 '24 Sale 3.54 1,325 4,692 57,032 Jan 03 05:30 PM Watanabe Todd Franklin See Remarks Dec 01 '23 Option Exercise 1.68 59,525 100,038 513,682 Dec 01 08:51 PM Matsuda Masaru See Remark Nov 21 '23 Sale 1.98 1,850 3,661 46,634 Nov 21 05:47 PM Frazier Life Sciences VIII, L. 10% Owner Oct 24 '23 Buy 2.50 80,000 200,000 8,764,232 Oct 26 04:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite